<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02547740</url>
  </required_header>
  <id_info>
    <org_study_id>AAAO8502</org_study_id>
    <secondary_id>1R01EY025253-01</secondary_id>
    <nct_id>NCT02547740</nct_id>
  </id_info>
  <brief_title>Macular Damage in Early Glaucoma and Progression</brief_title>
  <official_title>Structural and Functional Progression of Glaucomatous Damage to the Macula</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Columbia University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Eye Institute (NEI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Columbia University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Glaucoma is the leading cause of irreversible blindness worldwide. This study aims to test a&#xD;
      new method that may allow earlier diagnosis of glaucoma and better ways to monitor if it is&#xD;
      getting worse. There is scientific evidence that the macula, the central part of the retina,&#xD;
      can be involved in very early stages of glaucoma. Glaucomatous damage to the macula is very&#xD;
      prevalent and is often missed using conventional clinical tests.&#xD;
&#xD;
      Relatively little is known about progression of early glaucoma damage and its effects on the&#xD;
      macula. This project investigates the nature of progressive damage to the macula and proposes&#xD;
      new methods to improve accuracy to detect clinically significant progression.The study will&#xD;
      evaluate the nature of damage to the macula's structures through OCT imaging and eye function&#xD;
      via visual field tests.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There is compelling evidence that glaucomatous damage to the macula occurs even in early&#xD;
      stages of the disease. The macula comprises about 30% of all retinal ganglion cells and its&#xD;
      information corresponds to over 50% of the visual cortex. However, glaucomatous damage to the&#xD;
      macula is often missed in clinical practice. Some of the reasons are:&#xD;
&#xD;
        1. traditional glaucoma knowledge supports that glaucoma is fundamentally a peripheral&#xD;
           disease;&#xD;
&#xD;
        2. inherent limitations of conventional clinical tests to detect damage to the macula; and&#xD;
&#xD;
        3. the paucity of large, prospective studies that describe the nature of glaucomatous&#xD;
           damage to the macula.&#xD;
&#xD;
      The investigators have published numerous papers in the past two years showing that macular&#xD;
      damage is prevalent among patients with early glaucoma if one employs the appropriate tools&#xD;
      to assess it, namely 10-2 visual fields and high-resolution optical coherence tomography&#xD;
      (OCT). This information comes from a unique prospective cross- sectional database and&#xD;
      techniques the investigators developed to produce objective metrics of structure and&#xD;
      function.&#xD;
&#xD;
      Now that the investigators understand the cross-sectional nature of macular damage, this&#xD;
      proposal aims to:&#xD;
&#xD;
        1. develop a longitudinal database including patients with early glaucoma and healthy&#xD;
           controls,&#xD;
&#xD;
        2. to test models that explain progression of macular damage, and&#xD;
&#xD;
        3. to apply new statistical methods combining structural and functional tests which could&#xD;
           improve the accuracy to detect progression and shorten the length of clinical trials.&#xD;
&#xD;
      The main hypothesis is that incorporating 10-2 visual field testing and high-resolution OCT&#xD;
      scans of the macula to the conventional repertoire of technologies used in clinical practice,&#xD;
      in addition to translating recently described statistical methods into softwares that can be&#xD;
      used in daily practice, enhances the performance and confidence to detect glaucoma&#xD;
      progression.&#xD;
&#xD;
      In Aim 1 the investigators plan to follow healthy subjects and glaucoma patients at regular&#xD;
      intervals with 10-2, 24-2 visual fields, and swept source (ss) OCT tests and define metrics&#xD;
      of short- and long-term test variability that are needed to differentiate true progression&#xD;
      from 'noise'. To date, there is no such database combining these technologies.&#xD;
&#xD;
      In Aim 2 the investigators plan to combine metrics of structure and function from this&#xD;
      longitudinal database using two methods: a spatial approach, which will ultimately produce a&#xD;
      joint structure-function index using 10-2 and ssOCT data; and a temporal approach, which will&#xD;
      employ Bayesian statistics to measure rates of progression using trend analysis. By the end&#xD;
      of the study, our contributions to the field should be:&#xD;
&#xD;
        1. to make available a unique and pristine longitudinal database that could be used for&#xD;
           other hypotheses testing,&#xD;
&#xD;
        2. to translate techniques recently described in the literature into objective tools to be&#xD;
           readily useful in clinical practice, and&#xD;
&#xD;
        3. to mitigate the burdens of progressive loss of central vision in glaucoma.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 2015</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">October 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change in 10-2 visual field</measure>
    <time_frame>Baseline and 3 years</time_frame>
    <description>Evidence of functional glaucomatous damage on the macula as confirmed by visual fields: A slope of 10-2 visual field change faster than -1 dB/year at P&lt;5%</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in macular ganglion cell thickness</measure>
    <time_frame>Baseline and 3 years</time_frame>
    <description>Evidence of structural glaucomatous damage on the macula as confirmed by OCT imaging: evidence of macular ganglion cell thickness slope less than -10 microns/year</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">375</enrollment>
  <condition>Glaucoma</condition>
  <arm_group>
    <arm_group_label>Early Glaucomatous Damage</arm_group_label>
    <description>Patients with early functional glaucomatous damage.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ophthalmologically Healthy</arm_group_label>
    <description>Healthy subjects that are ophthalmologically normal</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients seen in Columbia eye clinics and enrolled in cross-sectional database; Columbia&#xD;
        University Medical Center Eye Institute.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Glaucoma Group:&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  glaucomatous optic neuropathy (as defined in the American Academy of Ophthalmology&#xD;
             Preferred Practice Pattern criteria)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  late functional glaucomatous damage&#xD;
&#xD;
          -  significant cataract&#xD;
&#xD;
          -  previous ocular surgery (aside from uncomplicated cataract extraction with intraocular&#xD;
             lens (IOL) implantation and/or trabeculectomy, LASIK or refractive surgeries)&#xD;
&#xD;
          -  diabetic retinopathy with macular edema&#xD;
&#xD;
          -  vein or artery occlusion&#xD;
&#xD;
          -  exudative age-related macular degeneration or geographic atrophy&#xD;
&#xD;
          -  macular hole or traction&#xD;
&#xD;
          -  amblyopia&#xD;
&#xD;
          -  uveitis&#xD;
&#xD;
          -  non-open angle glaucoma (e.g. angle closure, traumatic, congenital glaucoma)&#xD;
&#xD;
          -  severe myopia or hyperopia (refractive error greater than -6 or +6D, respectively)&#xD;
&#xD;
          -  retinal detachment (current or post-surgery)&#xD;
&#xD;
          -  retinitis pigmentosa&#xD;
&#xD;
          -  significant epiretinal memberane&#xD;
&#xD;
          -  significant kerotoconus&#xD;
&#xD;
        Healthy Group:&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  best corrected visual acuity equal or better than 20/40&#xD;
&#xD;
          -  normal biomicroscopy examination&#xD;
&#xD;
          -  gonioscopically open angles&#xD;
&#xD;
          -  Intraocular Pressure (IOP) lower than 22 mmHg&#xD;
&#xD;
          -  normal and reliable 24-2 and 10-2 SAP results&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  evidence of optic neuropathy&#xD;
&#xD;
          -  evidence of clinically significant metabolic diseases (e.g. diabetes and hypotension)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>C. Gustavo De Moraes, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lam Lu, BS</last_name>
    <phone>646-457-0940</phone>
    <email>ll3051@cumc.columbia.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>CUMC Harkness Eye Institute</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lam Lu, BS</last_name>
      <phone>646-457-0940</phone>
      <email>ll3051@cumc.columbia.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>September 10, 2015</study_first_submitted>
  <study_first_submitted_qc>September 10, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 11, 2015</study_first_posted>
  <last_update_submitted>January 14, 2021</last_update_submitted>
  <last_update_submitted_qc>January 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>macula</keyword>
  <keyword>visual fields</keyword>
  <keyword>optical coherence tomography</keyword>
  <keyword>glaucoma progression</keyword>
  <keyword>retinal ganglion cells</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Disease Progression</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

